News

Sporadic PEG-Asparaginase Dosing Reduces Treatment-Related Toxicity in ALL

04/26/2019

Following the first 5 doses of treatment, intermittent PEG-asparaginase effectively reduced toxicity over continuous PEG-asparaginase in pediatric ALL.

Following the first 5 doses of...

04/26/2019

Oncology

News

Factors Affecting EFS After CAR-T Therapy Identified in Certain Patients With B-ALL

04/25/2019

Baseline platelet count and lactate dehydrogenase are tied to EFS outcomes in patients with B-ALL who achieve MRD-negative CR after CAR-T therapy.

Baseline platelet count and...

04/25/2019

Oncology

News

MRD Levels Help Determine Appropriate B-Cell Precursor ALL Therapy

03/20/2019

Patients with B-cell precursor ALL and high MRD levels may benefit from more experimental therapies than those with low MRD levels, a recent study has shown.

Patients with B-cell precursor...

03/20/2019

Oncology

News

FDA Approves Asparagine Specific Enzyme for Use in Multiagent ALL Chemo Regimen

12/20/2018

The FDA approved calaspargase pegol-mknl for use in a multiagent chemotherapy regimen for the treatment of patients aged 1 to 21 years with ALL.

The FDA approved calaspargase...

12/20/2018

Oncology

News

Survival Benefits With CAR-T Therapy Higher Than With Chemotherapy in Leukemia

10/25/2018

CAR-T therapy demonstrates long-term, cost-effective survival benefits in certain patients with B-cell ALL, according to results from a recent study

CAR-T therapy demonstrates...

10/25/2018

Oncology

News

Low Research Participation, Shorter Therapy Tied to ALL Relapse in Young Adults

10/09/2018

Acute lymphoblastic leukemia is more likely to relapse in adolescents and young adults than in children, and lower clinical trial enrollment and shorter therapy course are associated factors, researchers say.

Acute lymphoblastic leukemia is...

10/09/2018

Oncology

News

CAR-T Therapy Efficacy Based on Transplant Status in Certain Leukemias

09/26/2018

Outcomes with CAR-T therapy may be influenced by transplant status in patients with B-lineage acute lymphoblastic leukemia or B-cell chronic lymphocytic leukemia.

Outcomes with CAR-T therapy may...

09/26/2018

Oncology

News

Escalated vs High-Dose Methotrexate in T-Cell ALL

09/20/2018

Patients with T-cell ALL treated with chemotherapy and an escalating methotrexate regimen had survival outcomes superior to those of patients given high-dose methotrexate.

Patients with T-cell ALL treated...

09/20/2018

Oncology

News

Experts Join to Release Guidelines for CAR-T Therapy Use in Child Cancer

08/08/2018

Management guidelines for the use of CAR-T therapy in pediatric patients with ALL were recently published in Nature Reviews Clinical Oncology.

Management guidelines for the...

08/08/2018

Oncology

News

Neurotoxicity in B-Cell ALL Not from CAR-T Therapy

08/03/2018

Clinical trial results have demonstrated significant associations between cellular mechanisms other than T-cells and symptoms of neurotoxicity in patients with ALL receiving CAR-T therapy.

Clinical trial results have...

08/03/2018

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology